Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: risk + study + 0.19  Related to the article below (Last Update: 8/4/2008)

Sexually Transmitted Infection Among Adolescents Receiving Special ...
RedOrbit, TX - Aug 3, 2008
The purpose of this study was to examine the risk of contracting a sexually transmitted infection (STI) among children with learning disabilities. ...
Ethnicity and quality of antipsychotic prescribing among in ...
British Journal of Psychiatry (subscription), UK - Jul 31, 2008
High-dose antipsychotics were prescribed to 15.1% of White and 11.7% of Black patients (adjusted odds ratio (OR)=0.5, 95% CI 0.19?1.33), and antipsychotic ...
CIN Risk Similar With Iso- and Low-Osmolar Contrast
Renal and Urology News, NY - Jul 21, 2008
The maximal rise in serum creatinine after PCI was 0.19 mg/dL for iodixanol and 0.21 mg/dL for iomeprol. Severe CIN occurred more frequently in the ...
Geron Corporation Reports 2008 Second Quarter Financial Results ...
MarketWatch - Jul 30, 2008
For the second quarter of 2008, the company reported a net loss of $13.6 million, or $(0.17) per share, compared to $14.0 million, or $(0.19) per share, ...GERN
Adex Mining Engages Leading Engineering Firm to Complete NI 43-101 ...
MarketWatch - Jul 24, 2008
These risks and uncertainties are detailed from time to time, including, without limitation, under the heading "Risk Factors", in reports filed by Adex with ...CVE:ADE - OTC:CMTX
Prenatal Exposure to n-3 Polyunsaturated Fatty Acids Protects ...
Medscape (subscription) - Jul 14, 2008
"Our aim was to examine whether increasing maternal intake of n-3 PUFAs in pregnancy may affect offspring risk of asthma." The study cohort was a ...
Adex Drill Results Include High-Grade Indium-Zinc-Copper ...
FOXBusiness - Jul 8, 2008
zinc and 0.19wt. % copper based on a 1997 feasibility study completed by Kvaerner Metals Davy Ltd. Since March of 2008, a total of 22 drill holes ...CVE:ADE - TSE:X - OTC:CMTX
Pacgen Reports Fiscal 2008 Financial Results
FOXBusiness - Jul 29, 2008
This study involving approximately 200 seropositive HIV patients was a randomized, examiner-blinded, parallel design trial comparing three different doses ...TSE:PGA - TSE:X - OTC:CMTX
Heritage Financial Group Posts Higher Second Quarter Net Income
MarketWatch - Jul 21, 2008
However, as the industry continues to face a difficult credit environment, the Company continued to address the potential risk in its loan portfolio with a ...HBOS
HCV Infection Doesn't Limit Immune Response to HIV Antiretroviral ...
MedPage Today, NJ - Jul 25, 2008
Note that the study was retrospective and included only patients who were able to achieve undetectable HIV-RNA levels on antiretroviral therapy. ...
Source: Google News

Is Pulse Pressure Useful in Predicting Risk for Coronary Heart Disease? The Framingham Heart Study -
SS Franklin, SA Khan, ND Wong, MG Larson, D Levy - Circulation, 1999 - Am Heart Assoc
... the subjects (n=303) excluded from the study because of ... the magnitude of the prediction
of CHD risk did not ... baseline PP and SBP (?-coefficients of 0.19 for PP ...

… of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. -
E Bonora, G Targher, MB Zenere, F Saggiani, V … - Int J Obes Relat Metab Disord, 1996 - ncbi.nlm.nih.gov
... in the Verona Young Men Atherosclerosis Risk Factors Study, a cross-sectional
population-based study. ... BMI (r = 0.24; P < 0.0001), WHR (r = 0.19; P < 0.0001 ...

… fetal growth rate and increased risk of death from ischaemic heart disease: cohort study of 15 000 … -
DA Leon, HO Lithell, D V?ger?, I Koupilov?, R … - BMJ: British Medical Journal, 1998 - pubmedcentral.nih.gov
... much attenuated and no longer significant (P=0.19). ... Davey Smith G. Birthweight, adult
risk factors and incident coronary heart disease: the Caerphilly study. ...

Estrogen replacement therapy and risk of Alzheimer disease -
A Paganini-Hill, VW Henderson - Archives of Internal Medicine, 1996 - Am Med Assoc
... lowest observed risk in long-term users who received high doses (odds ratio, 0.48;
95% confidence interval, 0.19-1.17). CONCLUSION: This study suggests that ...

Postmenopausal estrogen replacement therapy and risk of AD A population-based study -
SC Waring, WA Rocca, RC Petersen, PC O'Brien, EG … - Neurology, 1999 - AAN Enterprises
... as use for >1 year (OR = 0.44; 95% CI = 0.19 to 1.02 ... conflicting regarding the influence
of ERT on the risk of AD ... Our study was an attempt to address some of the ...

Reduced risk of colon cancer with high intake of vitamin E: the Iowa Women's Health Study -
RM Bostick - Cancer Research, 1993 - AACR
... we analyzed data from a prospective cohort study of 35,215 ... P for trend < 0.0001);
the relative risk for the ... 0.32 [95% confidence interval (95% CI) 0.19, 0.54]. ...

… of prevention measures in patients at high risk for contrast nephropathy Results of the PRINCE study -
MA Stevens, PA McCullough, KJ Tobin, JP Speck, DC … - Journal of the American College of Cardiology, 1999 - Am Coll Cardio Found
... effect of diabetes after adjustment for multiple comparisons, p = 0.19. ... can be
attributed to a greater degree of baseline risk in study participants with ...

[CITATION] … of Antioxidant Nutrients and the Risk of Incident Alzheimer Disease in a Biracial Community Study -
MC Morris, DA Evans, JL Bienias, CC Tangney, DA … - JAMA: The Journal of the American Medical Association, 2002 - JAMA
... vitamin E, vitamin A, and beta carotene (RR, 0.40; 95% CI, 0.19-0.85 ... In the CHAP
study, presence of the APOE 4 allele was associated with increased risk of AD ...

Familial risk factors for adolescent suicide: a case-control study -
DA Brent, JA Perper, G Moritz, L Liotus, J … - Acta Psychiatrica Scandinavica, 1994 - Blackwell Synergy
... 0.55 (0.08) 0.47 10.08) 0.03 (0.01) 0.19 (0.03) 0.15 ... In this study, we demonstrated
a significant asso- ciation between several familial risk factors and ...

… ARE PREDICTORS FOR DEVELOPMENT OF HIGH-GRADE CERVICAL LESIONS: A LONGITUDINAL FRENCH COHORT STUDY -
F Besan?on - Int. J. Cancer, 2003 - doi.wiley.com
... presence of HR-HPV was a key risk factor for ... The rate of CIN2/3 was only 0.19 per
100 women ... months when taking into account the global study population, 0.81 ...

Source: Google Scholar
 
 

Marathoners at risk for melanoma: study

Last Updated: 2006-11-20 16:00:19 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Marathon runners may face an increased risk of skin cancer, Austrian researchers report.

Based on the findings, they conclude, long-distance runners should make an effort to reduce their exposure to ultraviolet (UV) radiation by using sunscreen, wearing protective clothing, and organizing their training and competition routines accordingly.Dr. Christina M. Ambros-Rudolph of the Medical University of Graz in Austria and colleagues decided to investigate melanoma risk among long-distance runners after treating eight ultramarathon runners with the disease over a 10-year period.

Along with sun exposure, immunosuppression due to intense training has been proposed as a potential trigger for melanoma, they note in the Archives of Dermatology.

Article continues below and (thank you)

 

 

They recruited 210 marathon runners ranging in age from 19 to 71 years for the study, matching them by age and sex with a control group of non-marathoners.

Even though men and women in the control group had more signs of sun sensitivity, such as light eye and skin color and more birthmarks, the marathoners were more likely to have changes in the skin that signal an increased malignant melanoma risk.

And just 56.2 percent of the runners reported using sunscreen regularly, even though nearly all said they ran in shorts and sleeveless or short-sleeved shirts.

While the jury is still out on the role of immunosuppression in boosting melanoma risk, Ambros-Rudolph and her colleagues write, "runners should be alerted to the crucial role of UV radiation in the development of malignant melanoma and non-melanoma skin cancer.

In particular, they should be advised to reduce UV exposure during exercising by choosing training and competition schedules with low sun exposure, wearing adequate clothing, and regularly using water-resistant sunscreens."

SOURCE: Archives of Dermatology, November 2006.

Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 

Statins and fibrates no help against melanoma

Last Updated: 2006-11-20 11:43:18 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Although there was thought to be an association between use of cholesterol-lowering statins and fibrates and a reduced risk of melanoma, a meta-analyses of trials of such drugs does not bear out this apparent connection, according to a report in the Journal of the National Cancer Institute.

Researchers point out in the paper that case-control studies suggest that statins, like lovastatin, and fibrate drugs, like gemfibrozil, may reduce the risk of melanoma, and there's "promising evidence from in vitro and animal models." However, as senior investigator Dr. Robert P. Dellavalle told Reuters Health: "Our study showed that the standard doses of medications used to treat high cholesterol -- statins and fibrates -- do not prevent melanoma."Dellavalle, of the University of Colorado at Denver and Health Sciences Center, Aurora and colleagues came to this conclusion after examining pooled data from 20 randomized controlled trials -- 12 for statins and 8 for fibrates -- involving almost 71,000 participants.Overall, there were 154 melanomas. However, their occurrence was not statistically significantly associated with use of statins or use of fibrates. Only one study, involving over 3300 participants, showed that lovastatin use was associated with a significantly lower incidence of melanoma. The researchers conclude that the findings "do not validate the possibility that statins or fibrates prevent melanoma."Nevertheless, concluded Dellavalle, "the possibility remains that these medications... might improve responses to therapy in patients with melanoma, if combined with chemotherapy."

SOURCE: Journal of the National Cancer Institute, November 1, 2006.

Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 

Annan warns of "catastrophic" biotech danger

Last Updated: 2006-11-20 11:34:02 -0400 (Reuters Health)

ST. GALLEN, Switzerland - U.N. Secretary-General Kofi Annan warned that potential dangers from the rapidly growing biotechnology industry were increasing exponentially and urged creating global safeguards.

Annan, speaking on Saturday in the Swiss university town, warned of "catastrophic" results if recent advances in biotechnology, including gene manipulation and work with viruses, fell into the wrong hands.

"As biological research expands, and technologies become increasingly accessible, this potential for accidental or intentional harm grows exponentially," he said in the text of a speech.

"Even novices working in small laboratories will be able to carry out gene manipulation."

Annan's warning comes after he called in May for a global forum on biological terrorism, saying current treaties were too weak and governmental and commercial initiatives too scattered.

Annan likened the current consensus-building phase over life-sciences rules to the debate around nuclear technology in the 1950s that preceded the creation of the International Atomic Energy Agency and the Nuclear Non-Proliferation Treaty.

"We lack an international system of safeguards to manage those risks. Scientists may do their best to follow rules for responsible conduct of research. But efforts to harmonize these rules on a global level are outpaced by the galloping advance of science itself," he said.

Annan was speaking at an event where he received the Max Schmidheiny Freedom Prize.

Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; Nedws9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 

 © 2002-2006

Keywords::

Contact Iconocast

Home Page